Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The worldwide Chemotherapy Induced Peripheral Neuropathy Treatment market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.0% during the forecast period.
This report presents the market size and development trends by detailing the Chemotherapy Induced Peripheral Neuropathy Treatment market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Chemotherapy Induced Peripheral Neuropathy Treatment market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Chemotherapy Induced Peripheral Neuropathy Treatment industry and will help you to build a panoramic view of the industrial development.
Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Type:
Calcium Channel 2-delta Ligands
Antidepressants
Opioids
Others
Chemotherapy Induced Peripheral Neuropathy Treatment Market, By Application:
Platinum Agents
Taxanes
Vinca Alkaloids
Others
Some of the leading players are as follows:
Solasia Pharma
Krenitsky Pharmaceuticals
WinSanTor
Immune Pharmaceuticals
Metys Pharmaceuticals
Asahi Kasei Pharma
Kineta Inc
DermaXon
DermaXon LLC
Kineta
MAKScientific
Sova Pharmaceuticals
PledPharma
Apexian Pharma
Nemus Bioscience
Aptinyx
Geographically, Major regions are analyzed in details are as follows:
-
North America
-
Europe
-
Asia Pacific
-
Latin America
-
Middle East & Africa
Table of Contents
1 Methodology and Scope
-
1.1 Market Segmentation & Scope
-
1.1.1 Technology Type
-
1.1.2 Product
-
1.1.3 Application
-
1.1.4 Regional scope
-
1.1.5 Estimates and forecast timeline
-
1.2 Research Methodology
-
1.3 Information Procurement
-
1.3.1 Purchased database
-
1.3.2 Internal database
-
1.3.3 Secondary sources
-
1.3.4 Primary research
-
1.3.5 Details of primary research
-
1.4 Information or Data Analysis
-
1.4.1 Data analysis models
-
1.5 Market Formulation & Validation
-
1.6 Model Details
-
1.6.1 Commodity flow analysis
-
1.6.2 Volume price analysis
-
1.7 List of Secondary Sources
-
1.8 List of Abbreviations
2 Executive Summary
-
2.1 Market Outlook
-
2.2 Segment Outlook
3 Market Variables, Trends, & Scope
-
3.1 Market Lineage Outlook
-
3.1.1 Parent market outlook
-
3.1.2 Ancillary market outlook
-
3.2 Market Segmentation
-
3.2.1 Analysis
-
3.3 Market Dynamics
-
3.3.1 Market driver analysis
-
3.3.2 Market restraint analysis
-
3.3.3 Industry opportunities
-
3.4 Penetration & Growth Prospect Mapping
-
3.4.1 Penetration & growth prospect mapping analysis
-
3.5 Business Environment Analysis Tools
-
3.5.1 Porter's five forces analysis
-
3.5.2 PESTLE analysis
-
3.5.3 Major deals & strategic alliances analysis
4 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Technology Type Analysis
-
4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Technology Type Market Share Analysis, 2018 & 2026
-
4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Technology Type Market: Segment Dashboard
-
4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment
4.3.1 Calcium Channel 2-delta Ligands
4.3.2 Antidepressants
4.3.3 Opioids
4.3.4 Others
5 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Product Analysis
-
5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Market Share Analysis, 2018 & 2026
-
5.2 Chemotherapy Induced Peripheral Neuropathy Treatment Product Market: Segment Dashboard
-
5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment
6 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Application Analysis
-
6.1 Chemotherapy Induced Peripheral Neuropathy Treatment Application Market Share Analysis, 2018 & 2026
-
6.2 Chemotherapy Induced Peripheral Neuropathy Treatment Application Market: Segment Dashboard
-
6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment
6.3.1 Platinum Agents
6.3.2 Taxanes
6.3.3 Vinca Alkaloids
6.3.4 Others
7 Chemotherapy Induced Peripheral Neuropathy Treatment Market: Regional Analysis
-
7.1 Chemotherapy Induced Peripheral Neuropathy Treatment Regional Market Share Analysis, 2018 & 2026
-
7.2 Chemotherapy Induced Peripheral Neuropathy Treatment Regional Market: Segment Dashboard
-
7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)
-
7.4 List of Players at Regional Level
-
7.4.1 North America
-
7.4.2 Europe
-
7.4.3 Asia Pacific
-
7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
-
7.5.1 North America
-
7.5.2 Europe
-
7.5.3 Asia Pacific
-
7.5.4 Latin America
-
7.5.5 MEA
-
7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026
-
7.6.1 North America
-
7.6.2 Europe
-
7.6.3 Asia Pacific
-
7.6.4 Latin America
-
7.6.5 Middle East & Africa
8 Competitive Analysis
-
8.1 Recent Developments & Impact Analysis, by Key Market Participants
-
8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)
-
8.3 Vendor Landscape
-
8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)
9 Company Profiles
9.1 Solasia Pharma
9.1.1 Solasia Pharma Company overview
9.1.2 Financial performance
9.1.3 Product benchmarking
9.1.4 Strategic initiatives
9.1.5 SWOT analysis
9.2 Krenitsky Pharmaceuticals
9.2.1 Krenitsky Pharmaceuticals Company overview
9.2.2 Financial performance
9.2.3 Product benchmarking
9.2.4 Strategic initiatives
9.2.5 SWOT analysis
9.3 WinSanTor
9.3.1 WinSanTor Company overview
9.3.2 Financial performance
9.3.3 Product benchmarking
9.3.4 Strategic initiatives
9.3.5 SWOT analysis
9.4 Immune Pharmaceuticals
9.4.1 Immune Pharmaceuticals Company overview
9.4.2 Financial performance
9.4.3 Product benchmarking
9.4.4 Strategic initiatives
9.4.5 SWOT analysis
9.5 Metys Pharmaceuticals
9.5.1 Metys Pharmaceuticals Company overview
9.5.2 Financial performance
9.5.3 Product benchmarking
9.5.4 Strategic initiatives
9.5.5 SWOT analysis
9.6 Asahi Kasei Pharma
9.6.1 Asahi Kasei Pharma Company overview
9.6.2 Financial performance
9.6.3 Product benchmarking
9.6.4 Strategic initiatives
9.6.5 SWOT analysis
9.7 Kineta Inc
9.7.1 Kineta Inc Company overview
9.7.2 Financial performance
9.7.3 Product benchmarking
9.7.4 Strategic initiatives
9.7.5 SWOT analysis
9.8 DermaXon
9.8.1 DermaXon Company overview
9.8.2 Financial performance
9.8.3 Product benchmarking
9.8.4 Strategic initiatives
9.8.5 SWOT analysis
9.9 DermaXon LLC
9.9.1 DermaXon LLC Company overview
9.9.2 Financial performance
9.9.3 Product benchmarking
9.9.4 Strategic initiatives
9.9.5 SWOT analysis
9.10 Kineta
9.10.1 Kineta Company overview
9.10.2 Financial performance
9.10.3 Product benchmarking
9.10.4 Strategic initiatives
9.10.5 SWOT analysis
9.11 MAKScientific
9.11.1 MAKScientific Company overview
9.11.2 Financial performance
9.11.3 Product benchmarking
9.11.4 Strategic initiatives
9.11.5 SWOT analysis
9.12 Sova Pharmaceuticals
9.12.1 Sova Pharmaceuticals Company overview
9.12.2 Financial performance
9.12.3 Product benchmarking
9.12.4 Strategic initiatives
9.12.5 SWOT analysis
9.13 PledPharma
9.13.1 PledPharma Company overview
9.13.2 Financial performance
9.13.3 Product benchmarking
9.13.4 Strategic initiatives
9.13.5 SWOT analysis
9.14 Apexian Pharma
9.14.1 Apexian Pharma Company overview
9.14.2 Financial performance
9.14.3 Product benchmarking
9.14.4 Strategic initiatives
9.14.5 SWOT analysis
9.15 Nemus Bioscience
9.15.1 Nemus Bioscience Company overview
9.15.2 Financial performance
9.15.3 Product benchmarking
9.15.4 Strategic initiatives
9.15.5 SWOT analysis
9.16 Aptinyx
9.16.1 Aptinyx Company overview
9.16.2 Financial performance
9.16.3 Product benchmarking
9.16.4 Strategic initiatives
9.16.5 SWOT analysis
The List of Tables and Figures (Totals 62 Figures and 126 Tables)
Figure Calcium Channel 2-delta Ligands Chemotherapy Induced Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)
Figure Antidepressants Chemotherapy Induced Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)
Figure Opioids Chemotherapy Induced Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)
Figure Others Chemotherapy Induced Peripheral Neuropathy Treatment market, 2015 - 2026 (USD Million)
Figure Platinum Agents market, 2015 - 2026 (USD Million)
Figure Taxanes market, 2015 - 2026 (USD Million)
Figure Vinca Alkaloids market, 2015 - 2026 (USD Million)
Figure Others market, 2015 - 2026 (USD Million)
-
Table List of players in North America
-
Table List of players in Europe
-
Table List of players in Asia Pacific
-
Table SWOT analysis
-
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)
-
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table North America Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.S. Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table U.S. Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table U.S. Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Canada Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Canada Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Canada Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)
-
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Europe Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table U.K. Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table U.K. Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table U.K. Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Germany Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Germany Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Germany Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table France Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table France Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table France Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Italy Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Italy Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Italy Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Spain Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Spain Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Spain Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)
-
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Asia Pacific Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table China Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table China Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table China Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Japan Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Japan Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Japan Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table India Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table India Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table India Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Latin America Chemotherapy Induced Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)
-
Table Latin America Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Latin America Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Latin America Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Brazil Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Brazil Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Brazil Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Mexico Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Mexico Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Mexico Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Argentina Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Argentina Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Argentina Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table MEA Chemotherapy Induced Peripheral Neuropathy Treatment market, by country, 2015 - 2026 (USD Million)
-
Table MEA Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table MEA Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table MEA Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table South Africa Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table South Africa Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table South Africa Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Regulatory scenario
-
Table Nigeria Chemotherapy Induced Peripheral Neuropathy Treatment market, by type, 2015 - 2026 (USD Million)
-
Table Nigeria Chemotherapy Induced Peripheral Neuropathy Treatment market, by product, 2015 - 2026 (USD Million)
-
Table Nigeria Chemotherapy Induced Peripheral Neuropathy Treatment market, by application, 2015 - 2026 (USD Million)
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Recent Developments & Impact Analysis, by Key Market Participants
-
Table Company market position analysis
Table Company Profiles
Table Solasia Pharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Krenitsky Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table WinSanTor Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Immune Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Metys Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Asahi Kasei Pharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Kineta Inc Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table DermaXon Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table DermaXon LLC Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Kineta Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table MAKScientific Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Sova Pharmaceuticals Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table PledPharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Apexian Pharma Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Nemus Bioscience Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
Table Company Profiles
Table Aptinyx Production, Value, Price, Gross Margin 2014-2019
Table Product benchmarking
Table Strategic initiatives
Table SWOT analysis
-
